In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 211 to 220 of 294

TitleTypeExpected publication date
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]Technology appraisal guidance
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines [ID6356]Technology appraisal guidance
Renal cell carcinoma Pathways Pilot [ID6186]Technology appraisal guidanceTBC
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]Technology appraisal guidanceTBC
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]Technology appraisal guidance
Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]Technology appraisal guidanceTBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6436]Technology appraisal guidanceTBC
Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy ID6482 [ID6482]Technology appraisal guidance
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women [ID1307]Technology appraisal guidanceTBC
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All